Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out what effects (good and bad) pemetrexed has on patients with advanced neuroendocrine tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chemotherapy for Patients With Osteosarcoma

NCT00523419

Osteosarcoma

COMPLETED PHASE2

Pemetrexed in Patients With Soft Tissue Sarcoma

NCT00427466

Sarcoma

COMPLETED PHASE2

Pemetrexed for the Treatment of Chordoma

NCT03955042

Chordoma

COMPLETED PHASE1

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT04158141

Pleural Biphasic Mesothelioma Pleural Epithelioid Mesothelioma Stage I Pleural Malignant Mesothelioma AJCC v8 +4 more

TERMINATED PHASE3

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413

Advanced Solid Tumors Metastatic Pancreatic Cancer Pediatric Solid Tumor +3 more

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* 1 cycle is equal to 21 days. Every 21 days the following will be performed: a review of the patients symptoms and medications; physical exam; blood tests; vital signs; and pemetrexed infusion.
* Every 3 cycles (9 weeks) an assessment of disease extent by CT scan and a 24 hour urine collection (if applicable) will be performed.
* Before patients start receiving pemetrexed, they will be given folic acid, vitamin B12 and dexamethasone to help reduce the chance of significant side effects. Dexamethasone will be taken the evening before, the morning before and the evening after receiving pemetrexed. Folic acid should be taken daily beginning 5-7 days before the first dose of pemetrexed and should be continued for three weeks after the last dose of pemetrexed. Vitamin B12 will be given as an injection 1-2 weeks before the first dose of pemetrexed and once every 9 weeks until 3 weeks after the last dose of pemetrexed.
* Patients can continue to receive treatment with pemetrexed unless there is evidence that their tumor has grown or they are experiencing serious side effects.
* Immediately after the patient has completed the study, they will be given a physical exam, including vital signs, a CT scan, and blood tets. The study staff will continue to monitor the patients health either by clinic visits or phone calls every three months for the remainder of your life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroendocrine Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pemetrexed

Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Metastatic or locally unresectable neuroendocrine tumor, excluding small cell carcinoma
* Measurable tumor
* 18 year of age or older
* ECOG performance status of 0,1 or 2
* Life expectancy of greater than 12 weeks
* WBC: \> 3.0/mm3
* Plts: \> 100,000/mm3
* Bilirubin: \< 2.0 mg/dl
* AST \< 3 x ULN (except in patients with known hepatic metastases wherein SST may be \< 5 x ULN)
* Neutrophils \> 1000/mm3
* Creatinine Clearance \> 45 ml/min. Should be measured using the standard Cockroft-Gault formula

Exclusion Criteria

* Prior treatment with pemetrexed
* Clinically apparent central nervous system metastases or carcinomatous meningitis
* Myocardial infarction in the past 6 months
* Major surgery in the past two weeks
* Uncontrolled serious medical or psychiatric illness
* Pregnant or lactating women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No